Back to Journals » International Journal of Nanomedicine » Volume 16

Nanozymes as Enzyme Inhibitors

Authors Huang Y, Jiang J, Wang Y, Chen J, Xi J

Received 30 November 2020

Accepted for publication 28 January 2021

Published 12 February 2021 Volume 2021:16 Pages 1143—1155

DOI https://doi.org/10.2147/IJN.S294871

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Thomas J. Webster


Yaling Huang,1 Jian Jiang,1 Yanqiu Wang,1 Jie Chen,1 Juqun Xi1,2

1Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu, 225001, People’s Republic of China

Correspondence: Juqun Xi
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China
Tel +86 0514-87978804
Fax +86 0514-87341733
Email xijq@yzu.edu.cn

Abstract: Nanozyme is a type of nanomaterial with intrinsic enzyme-like activity. Following the discovery of nanozymes in 2007, nanozyme technology has become an emerging field bridging nanotechnology and biology, attracting research from multi-disciplinary areas focused on the design and synthesis of catalytically active nanozymes. However, various types of enzymes can be mimicked by nanomaterials, and our current understanding of nanozymes as enzyme inhibitors is limited. Here, we provide a brief overview of the utility of nanozymes as inhibitors of enzymes, such as R-chymotrypsin (ChT), β-galactosidase (β-Gal), β-lactamase, and mitochondrial F0F1-ATPase, and the mechanisms underlying inhibitory activity. The advantages, challenges and future research directions of nanozymes as enzyme inhibitors for biomedical research are further discussed.

Keywords: nanozyme, R-chymotrypsin inhibitor, β-galactosidase inhibitor, β-lactamase inhibitor, mitochondrial F0F1-ATPase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]